iXCells™ Human iPSC-Derived Motor Neurons
Overview
Spinal motor neurons (MNs) are a highly specialized type of neurons that reside in the ventral horns and project axons to muscles to control their movement. Degeneration of MNs is implicated in a number of devastating diseases, including spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth and poliomyelitis disease [1]. iPSC-derived motor neurons are valuable tools for biochemical analysis, disease modelling and clinical application of these diseases [2,3]. We are proud to provide the world’s first commercial human iPSC-derived motor neurons. Advantages of iXCells™ hiPSC-derived motor neurons:
Functionally validated by neuromuscular junction assays;
Highly pure ( >85%) population of HB9+, ISL-1+, ChAT+ cells;
Ready-to-use: available in both cryopreserved vials and fresh formats.
A highly pure population of functional motor neurons
iXCells Biotechnologies is pround to provide ready-to-use highly pure human motor neurons derived from normal iPS cell lines. These cells express typical markers of motor neurons, e.g. HB9 (MNX1), ISL-1, CHAT (Figure 1 and Figure 2). iXCells™ hiPSC-derived motor neurons are functionally validated with neuromuscular junction formation (Video 1-3). All the cells provided by iXCells are negative for mycoplasma, bacteria, yeast, and fungi. HIV-1, hepatitis B and hepatitis C. The basic donor information (gender / age / race) is provided for each cell lot purchased.
iXCells™ motor neurons are available in both cryopreserved vials (2 million cells/vial) and fresh plate formats (12-well plate or 96-well plate). Most of the cells will express high level of HB9 and ISL-1 (Figure 1) after thawing in the Motor Neuron Maintenance Medium (Cat# MD-0022). And after cultured in the medium for 5-7 days, these cells will express high levels of CHAT and MAP2 (Figure 2).
iXCells also provide customized differentiation service with your own iPS cell lines. Please contact us at [email protected] for more details.
Figure 1. After cultured in Motor Neuron Maintenance Medium (Cat# MD-0022) on the Matrigel-coated plates for 2 days, more than 85% of the iXCellsTM motor neurons express HB9 (Figure A and A’), and more than 90% of the cells express ISL1 (Figure B and B’).
Figure 2. After cultured in Motor Neuron Maintenance Medium on the Matrigel-coated plates for 5-7 days, more than 85% of the iPSC-derived motor neurons express ChAT (Figure A) and MAP2 (Figure B).
![]() |
Video 1. iXCellsTM human iPSC-derived motor neurons co-cultured with C2C12 mouse myotubes for 6 days. The spontaneous contraction of myotubes was observed. |
![]() |
Video 2. iXCellsTM human iPSC-derived motor neurons co-cultured with C2C12 mouse myotubes for 6 days. The contraction of myotubes was stimulated in the presence of 100µM glutamate. |
![]() |
Video 3. iXCellsTM human iPSC-derived motor neurons co-cultured with C2C12 mouse myotubes for 6 days. The contraction of myotubes was inhibited by adding 100µM Curare (a neurotoxin that inhibits acetylcholine receptor at the neuromuscular junction). |
Product Details
Catalog # | Description | Content Format | Package Size |
40HU-005 | iPSC-derived Motor Neuron (Normal) |
Cryopreserved Freshly plated (96-well plate) Freshly plated (12-well plate) |
2 million cells/vial > 5 million viable cells 8-10 million viable cells |
40HU-006 | iPSC-derived Motor Neuron (Diseased) |
Cryopreserved Freshly plated (96-well plate) Freshly plated (12-well plate) |
2 million cells/vial > 5 million viable cells 8-10 million viable cells |
40HU-A4V | iPSC-derived Motor Neuron (SOD1 mutant) |
Cryopreserved Freshly plated (96-well plate) Freshly plated (12-well plate) |
2 million cells/vial > 5 million viable cells 8-10 million viable cells |
MD-0022 | Motor Neuron Maintenance Medium | 100 mL |
References
[1] Brady ST. (1993). “Motor neurons and neurofilaments in sickness and in health. Cell. 9;73(1):1-3.
[2] Dolmetsch R, Geschwind DH. (2011) “The human brain in a dish: the promise of iPSC-derived neurons”. Cell. 145(6):831-4.
[3] Payne NL, Sylvain A, O'Brien C, Herszfeld D, Sun G, Bernard CC. (2015) “Application of human induced pluripotent stem cells for modeling and treating neurodegenerative diseases.” New Biotechnology. 25;32(1):212-28.